Pooled data from 2 phase 1 trials show that etentamig (ABBV-383; AbbVie Inc) has a manageable safety profile and low incidence of grades 3 and 4 infection in patients with relapsed/refractory multiple myeloma (RRMM). The findings, presented at the…
Etentamig Shows Manageable Safety and Low Severe Infection Risk in RRMM | Pharmacy Times
